Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB)

被引：0
|
作者：
Jacobson, Ira M.
Marcellin, Patrick
Heathcote, Jenny
Mathurin, Philippe
Gane, Ed J.
Buggisch, Peter
Husa, Petr
Krastev, Zahary
Sorbel, Jeff
Anderson, Jane
Mondou, Elsa
Rousseau, Franck
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A867 / A867
页数：1
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB)
    Lampertico, Pietro
    Buti, Maria
    Fung, Scott
    Ahn, Sang Hoon
    Chuang, Wan-Long
    Tak, Won Young
    Ramji, Alnoor
    Chen, Chi-Yi
    Tam, Edward
    Bae, Ho
    Ma, Xiaoli
    Flaherty, John F.
    Gaggar, Anuj
    Lau, Audrey H.
    Feierbach, Becket
    Wu, George
    Suri, Vithika
    Subramanian, Mani
    Trinh, Huy N.
    Yoon, Seung-Kew
    Agarwal, Kosh
    Lim, Young-Suk
    Chan, Henry L.
    GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1195
  • [22] Safety and efficacy in lamivudine (LAM) experienced chronic hepatitis B (CHB) patients treated for 2 years with tenofovir disoproxil fumarate (TDF)
    Roberts, S. K.
    Gane, E. J.
    Weilert, F.
    Sievert, W.
    George, J.
    Strasser, S. I.
    Kronborg, I.
    Heathcote, E. J.
    Marcellin, P.
    Sorbel, J.
    Rousseau, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A299 - A299
  • [23] Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (tenofovir) in HBeAg negative (-) patients with chronic hepatitis-B (CHB) in Italy and France
    Deniz, B.
    Everhard, F.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S210 - S210
  • [24] CHARACTERIZATION OF HBSAG KINETICS AND HBSAG SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Marcellin, Patrick
    Heathcote, E. Jenny
    Buti, Maria
    Krastev, Zahary
    Jacobson, Ira M.
    de Man, Robert A.
    Dusheiko, Geoffrey M.
    Zeuzem, Stefan
    Barnes, Chris N.
    Lou, Lillian
    HEPATOLOGY, 2011, 54 : 1036A - 1036A
  • [25] Factors associated with regression of cirrhosis in patients with chronic hepatitis B (CHB) infection treated with tenofovir disoproxil fumarate (TDF)
    Gane, Ed
    Afdhal, Nezam
    Buti, Maria
    Elsome, Amanda M.
    Flaherty, John F.
    Martins, Eduardo
    Bekele, Neby
    Bornstein, Jeffrey D.
    Marcellin, Patrick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 164 - 164
  • [26] HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS
    Marcellin, P.
    Heathcote, E. J.
    Buti, M.
    Krastev, Z.
    Jacobson, I.
    de Man, R. A.
    Dusheiko, G.
    Zeuzem, S.
    Barnes, C.
    Ng, C.
    Lou, L.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S297 - S297
  • [27] LONG TERM (4 YEAR) EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG plus ) WITH CHRONIC HEPATITIS B (STUDY 103): PRELIMINARY ANALYSIS
    Heathcote, E. Jenny
    Gane, Edward J.
    deMan, Robert A.
    Chan, Sing
    George, Jacob
    Tsai, Naoky C. S. C.
    Marcellin, Patrick
    Snow-Lampart, Andrea
    Coombs, Derek H.
    Mondou, Elsa
    Anderson, Jane
    HEPATOLOGY, 2010, 52 (04) : 556A - 557A
  • [28] 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
    Liu, Zhihong
    Jin, Qinglong
    Zhang, Yuexin
    Gong, Guozhong
    Wu, Guicheng
    Yao, Lvfeng
    Wen, Xiaofeng
    Gao, Zhiliang
    Huang, Yan
    Yang, Daokun
    Chen, Enqiang
    Mao, Qing
    Lin, Shide
    Shang, Jia
    Gong, Huanyu
    Zhong, Lihua
    Yin, Huafa
    Wang, Fengmei
    Hu, Peng
    Wu, Qiong
    Pan, Chao
    Jia, Wen
    Li, Chuan
    Sun, Chang'an
    Niu, Junqi
    Hou, Jinlin
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (03) : 649 - 660
  • [29] A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
    Brunetto, M.
    Lim, Y. S.
    Gane, E.
    Seto, W. K.
    Osipenko, M.
    Ahn, S. H.
    Janssen, H. L.
    Shukla, A.
    Chuang, W. L.
    Trinh, H.
    Celen, M. K.
    Flaherty, J. F.
    Lau, A. H.
    Gaggar, A.
    Suri, V.
    Bhardwaj, N.
    Kim, K.
    Subramanian, G. M.
    Pan, C.
    Izumi, N.
    Marcellin, P.
    Chan, H.
    Buti, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S26
  • [30] CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS
    Marcellin, Patrick
    Buti, Maria
    Krastev, Zahary
    Gurel, Selim
    Di Bisceglie, Adrian M.
    Odin, Joseph A.
    Dusheiko, Geoffrey M.
    Heathcote, E. Jenny
    Borroto-Esoda, Katyna
    Coombs, Derek H.
    Mondou, Elsa
    Anderson, Jane
    HEPATOLOGY, 2010, 52 (04) : 555A - 556A
12345